203 related articles for article (PubMed ID: 24396092)
1. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
Wallace JP; Wallace JL; McFarland MS
Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
5. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
[TBL] [Abstract][Full Text] [Related]
6. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
7. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
Renard E; Dubois-Laforgue D; Guerci B;
Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
[TBL] [Abstract][Full Text] [Related]
8. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
[TBL] [Abstract][Full Text] [Related]
9. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
[TBL] [Abstract][Full Text] [Related]
11. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
12. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
Dailey G; Admane K; Mercier F; Owens D
Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
[TBL] [Abstract][Full Text] [Related]
14. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
[TBL] [Abstract][Full Text] [Related]
15. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
16. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
17. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
18. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
19. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
20. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]